MiMedx Director Acquires $185K in Restricted Stock, Holds Over 200K Shares
MiMedx Group Director William A. Hawkins acquired 28,609 shares of common stock on June 18, 2025, at a price of $6.47 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MiMedx Group Director William A. Hawkins acquired 28,609 shares of common stock on June 18, 2025, at a price of $6.47 per share. This transaction represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3.
Following the transaction, Hawkins now beneficially owns a total of 204,018 shares directly. The restricted stock grant will vest upon the earlier of 12 months or the next annual meeting of shareholders.
Key Transaction Details:
- Transaction Type: Acquisition (Form 4)
- Stock Type: Common Stock
- Transaction Value: Approximately $185,100
- Ownership Form: Direct
- Filing Date: June 28, 2025
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 28,609 | $6.47 | $185K |
Footnotes (1)
- F1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the vesting period for MDXG director's restricted stock grant in 2025?
What is William Hawkins' role at MDXG according to the Form 4?
Is William Hawkins' MDXG stock ownership direct or indirect?
AI-generated analysis. How Rhea-AI works. Not financial advice.